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Background: Anorexia nervosa (AN) is a biologically based serious mental disorder with high levels of mortality
and disability, physical and psychological morbidity and impaired quality of life. AN is one of the leading causes of
disease burden in terms of years of life lost through death or disability in young women. Psychotherapeutic
interventions are the treatment of choice for AN, but the results of psychotherapy depend critically on the stage of
the illness. The treatment response in adults with a chronic form of the illness is poor and drop-out from treatment
is high. Despite the seriousness of the disorder the evidence-base for psychological treatment of adults with AN is
extremely limited and there is no leading treatment. There is therefore an urgent need to develop more effective
treatments for adults with AN. The aim of the Maudsley Outpatient Study of Treatments for Anorexia Nervosa and
Related Conditions (MOSAIC) is to evaluate the efficacy and cost effectiveness of two outpatient treatments for
adults with AN, Specialist Supportive Clinical Management (SSCM) and the Maudsley Model of Treatment for Adults
with Anorexia Nervosa (MANTRA).
Methods/Design: 138 patients meeting the inclusion criteria are randomly assigned to one of the two treatment
groups (MANTRA or SSCM). All participants receive 20 once-weekly individual therapy sessions (with 10 extra weekly
sessions for those who are severely ill) and four follow-up sessions with monthly spacing thereafter. There is also
optional access to a dietician and extra sessions involving a family member or a close other. Body weight, eating
disorder- related symptoms, neurocognitive and psychosocial measures, and service use data are measured during
the course of treatment and across a one year follow up period. The primary outcome measure is body mass index
(BMI) taken at twelve months after randomization.
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Discussion: This multi-center study provides a large sample size, broad inclusion criteria and a follow-up period.
However, the study has to contend with difficulties directly related to running a large multi-center randomized
controlled trial and the psychopathology of AN. These issues are discussed.
Trial Registration: Current Controlled Trials ISRCTN67720902 - A Maudsley outpatient study of treatments for
anorexia nervosa and related conditions.
Keywords: Anorexia nervosa, Eating disorder not otherwise specified, Outpatient treatment, Randomized controlled
trial, Cost effectivenessBackground
Anorexia nervosa (AN) is a biologically based serious
mental disorder with high levels of mortality and disabil-
ity, physical and psychological morbidity and impaired
quality of life [1]. Cognitive and emotional functioning
are impaired [2-4], and motivation may be compromised
due to the disorder being highly valued [5], making en-
gagement in treatment difficult.
AN is one of the leading causes of disease burden in
terms of years of life lost through death or disability in
young women [6], and the cost per case of AN is at least
equal to that of schizophrenia [7,8]. Compared to other
mental disorders, AN has the highest proportion of hos-
pital admissions with a length of stay over 90 days
(26.8%) and the longest median length of stay (36 days)
[9]. In one study of adolescents with AN, the annual ser-
vice cost was found to be approximately 17,000 GBP
[10], in adults with more chronic disorders this is likely
to be higher. The family members are usually the main
carers and report similar burden to carers of people with
psychosis [11]. A systematic review [12] of the costs of
eating disorders identified two cost-of-illness studies,
both of which underestimated the costs because of im-
portant omitted cost items. The review concludes that
the costs of AN are likely to be substantial. A recent re-
port detailed the cost of eating disorders to healthcare
and wider society [13]. It estimated a total cost for Eng-
land, per year of 1.25 billion GBP. This figure includes
costs to the NHS and private healthcare, the human
costs and the cost of lost output. The report specifically
estimated the cost to healthcare being over 80 million
GBP. Most of this can be attributed to the cost of AN.
Psychotherapeutic interventions are the treatment of
choice for AN, but the result of psychotherapy depends
critically on the stage of the illness. Whilst response to psy-
chological treatment (usually family-based) is excellent in
adolescents with a short duration of AN [14], the treatment
response in adults with a more chronic form of the illness
is much less positive and drop-out from treatment is high
[15]. The evidence-base for psychological treatment of
adults with AN is extremely limited. Several small trials
have tested a range of therapies, including cognitive-
behavioral therapy (CBT), interpersonal therapy (IPT),cognitive analytical therapy, and family therapy, but as yet
no one treatment has been found to be the best in terms of
efficacy [16,17]. One small trial [18] found specialist sup-
portive clinical management (SSCM) superior on a range of
outcomes compared to CBT and IPT at end of treatment.
Due to the superiority of SSCM compared with the other
active treatments this intervention has been selected as the
comparison treatment in this randomized controlled trial
(RCT). The urgent need to develop more effective treat-
ments for adults with AN has been highlighted [16,17].
One of the key factors responsible for the relative lack
of efficacy of treatments for adults with AN is that most
of these have been adapted from those for other disor-
ders and are neither tailored sufficiently to the charac-
teristics and needs of people with AN nor focused on
how the disorder is maintained. To remedy this problem
we have developed a specific maintenance model and
treatment approach for AN [5], the Maudsley Model of
Treatment for Adults with AN (MANTRA). Our treat-
ment model is novel in several respects: (a) it is
empirically-based, drawing on and incorporating recent
neuropsychological, social cognitive and personality trait
research in AN, (b) it includes both intra- and interper-
sonal maintaining factors, and proposes strategies for
addressing these and, (c) it is modularized with a clear
hierarchy of procedures and tailored to the needs of the
individual. Findings from pilot studies demonstrate the
acceptability and efficacy of this treatment intervention
among the AN patient group [19,20].
Aims
The main aim of this study is to compare the efficacy,
cost and cost-effectiveness of MANTRA in adult outpa-
tients with AN with that of SSCM in an RCT in a new
larger sample.
The subsidiary aim of the study is to explore mediators
and moderators of treatment outcome.
Methods/Design
Hypotheses
(1)A specific, empirically-based treatment model
focusing on four core maintenance factors
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producing greater weight gain and greater
improvement in eating-disorder related
psychopathology in adults with AN at six and
twelve months.
(2)MANTRA will be more cost-effective than SSCM,
showing lower costs at six and twelve months.
Specifically, it will be associated with fewer and
shorter hospitalizations during treatment and
follow-up compared to SSCM.
Research plan
Trial design
This is a multi-center two-arm superiority trial which
will evaluate the efficacy and cost-effectiveness of
MANTRA compared to SSCM, in consecutive referrals
of adult outpatients with AN. Patients will be randomly
allocated to either MANTRA or SSCM. More detail
regarding the randomization procedure is provided
below. Patients in both groups will be offered the same
amount of therapy.
The study design is shown in Figure 1.Clinician ass
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Figure 1 Study design.Outcomes will be measured pre-randomization, at six
months (that is, around the end of weekly treatment ses-
sions) and at twelve months follow-up. In addition, me-
diators of treatment outcome will be assessed mid
treatment (three months). Post treatment outcomes will
be assessed by researchers who are not involved in the
treatment process and steps are undertaken to ensure
that researchers remain blind to the patient’s treatment
group. Every effort will be made to include patients who
drop out of treatment in the follow-up assessments to
enable intention-to-treat analysis.Ethical approval
Ethical approval for the MOSAIC Trial has been obtained
from Central London REC 4, National Research Ethics
Service, Royal Free Hospital, London, NHS REC Refer-
ence: 10/H0714/9. Participants are not exposed to risk, re-
ceive verbal and written information before starting and
informed written consent is obtained from participants
before they enter the study. The research was conducted
in compliance with the Helsinki Declaration.essment
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Commonalities between both treatments
In both treatments, patients will receive 20 once-weekly
individual sessions of therapy together with four follow-
up sessions, with monthly spacing. In low-weight pa-
tients with a BMI of ≤15 kg/m2, weekly treatment will
be extended up to 30 sessions plus four follow-ups. In
both treatments two additional sessions with a close
other will be offered as well as an assessment from the
team’s dietician with follow-up dietetic sessions as
needed. Ongoing monitoring of physical risk is an inte-
gral part of both treatments. Therapy sessions will last
approximately 50 minutes, however in SSCM, from the
middle stage of treatment session duration may be re-
duced to 30 minutes at the therapist’s discretion, as
outlined in the original SSCM manual (McIntosh,
Jordan, Joyce, McKenzie, Luty, Carter, and Bulik, un-
published). Whilst this means that SSCM patients in
our trial will potentially receive somewhat less therapy
time than those allocated to MANTRA, we thought
that following the original SSCM protocol has the ad-
vantage that our study will be comparable to other tri-
als using SSCM.
MANTRA
The MANTRA model [5] proposes that four factors,
linked to underlying obsessional and anxious/avoidant
personality traits, are central to the maintenance of AN
and need to be addressed in treatment.
These are:
(a)a thinking style characterized by inflexibility,
attention to detail at the expense of the bigger
picture and fear of making mistakes;
(b)impairments in the socio-emotional domain (such as
avoidance of the experience and expression of
emotions and the socio-emotional triggers that
arouse them);
(c)pro-anorexia beliefs (that is, beliefs about the utility
of AN in helping the person manage their life).
These are one aspect of a broader set of illness
beliefs and it is the interaction between beliefs about
the illness and other non-illness related beliefs (that
is, beliefs about self, others and the world) that gives
the illness its own unique meaning for a particular
person. Examples of typical pro-AN beliefs include:
AN keeps me safe, AN numbs my emotions, AN
helps me to express my distress [21-23];
(d)the response of close others, including anxiety,
worry, blame, criticism, or hostility.
Thus it is hypothesized that MANTRA changes these
four putative mediating factors which in turn improve
the clinical outcomes (eating disorder symptoms).MANTRA treatment is centered around a patient-
manual (see data supplement DS1 in Schmidt et al. [19]
for details), the use of which is tailored to the needs of
the individual. The therapist style is that of motivational
interviewing [24], that is, reflective, responsive and col-
laborative. Based on an in-depth physical, psychological,
neuropsychological and socio-emotional/relational as-
sessment a collaborative case formulation is developed,
which is trait focused and builds on people’s strengths.
Feedback, for example, about medical risk, and thinking
style is used to increase motivation to change. The prin-
ciples of behavioral change are used to guide people to-
wards recovery [25,26]. There is a clear hierarchy of
treatment procedures depending on the person’s clinical
profile and balancing treatment motivation, level of
medical risk, and personal resources and supports avai-
lable. Close others are invited to participate flexibly in
sessions as necessary.
SSCM
This treatment was developed as a comparison treatment
in an RCT comparing CBT, IPT and SSCM [18,27]. SSCM
is designed to be delivered by health professionals trained
in the treatment of eating disorders and aims ‘to mimic out-
patient treatment that could be offered to individuals with
AN in usual clinical practice’. This treatment links features
of clinical management and supportive psychotherapy. The
former emphasizes the therapist’s expertise in providing
safe and appropriate patient management and care, includ-
ing education and support. The latter emphasizes the thera-
pist’s acceptance of the patient and a hopeful, positive
stance; a focus on the patient’s strengths, a collaborative, re-
flective conversational style, using praise, reassurance and
advice as appropriate. The abnormal nutritional status and
dietary patterns of AN are seen as central to SSCM. The
treatment emphasizes the resumption of normal eating and
restoration of weight and provides information on weight
gain and weight maintenance strategies, energy require-
ments and relearning to eat normally. The remaining ther-
apy content is determined by the patient. SSCM for AN
has three phases. Early on, the patient is oriented towards
the treatment, target symptoms are identified and goals for
weight gain and normalizing eating are agreed upon. In the
middle phase, target symptoms are monitored and the pa-
tient is supported and given encouragement in their attain-
ment of the dual goals of weight restoration and normal
eating. In the final phase, issues related to the ending of
therapy are discussed, including plans for the future and
the end of the therapeutic relationship. Further details of
this treatment are described in McIntosh et al. [28]. There
is also a manual for therapists (McIntosh, Jordan, Joyce,
McKenzie, Luty, Carter, and Bulik, unpublished) which
contains psycho-educational handouts for patients on
topics such as the ineffectiveness of laxatives and the
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are used flexibly throughout treatment.
Therapist training and supervision, treatment fidelity,
untoward events and protocol adherence
All therapists will be experienced eating disorder therapists.
We will use principles for enhancing treatment fidelity
outlined by the NIH Behavior Change Consortium [29]. All
therapists will attend two initial training days on MANTRA
and SSCM and over the course of the study, update ‘booster’
training days will be held at regular intervals to avoid ‘thera-
peutic drift’. All therapists will see patients in both condi-
tions. Such a ‘crossed design’ allows for within-therapist
assessment of intervention effects and avoids standard error
inflation by general therapist effects (see statistical analysis
section on how general and therapy-specific therapist effects
are modeled). Regular weekly supervision will be provided to
therapists by senior clinicians in their team and separately
for the two treatment conditions, to avoid contamination
across therapies. It is planned that each therapist will see
eight or more patients. Patients will be allocated to therapists
based on therapist availability. To ensure competent and
uniform treatment delivery, psychotherapy sessions will be
audiotaped and a random selection of three audiotapes per
patient will be reviewed for adherence to the two treatments.
An adaptation of the Collaborative Study Psychotherapy Rat-
ing Scale will be used to assess whether the two treatments
can be reliably distinguished [27]. In addition, we will use
the Motivational Interviewing Treatment Integrity (MITI
version 2) rating scale [30], and components of the second
version of the Motivational Interviewing Skill Code (MISC
version 2) [31]. These motivational measures are included as
the style of MANTRA is explicitly motivational and that of
SSCM has implicit elements of motivational interviewing.
Therapists will keep a case record form for each of
their trial patients on which they record each session,
briefly describe the session content, session duration,
and who attended (including close others involved in the
session), note the patient’s eating disorder symptoms,
and record any untoward events, according to pre-
specified criteria. Any protocol violations, for example,
caused by the patient’s admission to hospital will also
be recorded here. Criteria for an admission to hospital
will be the same as described below under exclusion
criteria.
Inclusion/exclusion criteria
Inclusion criteria
Consecutive patients referred to the specialist eating disorder
service by their GP will be offered participation if they are:
(a)aged between 18 and 60 years;
(b)have a BMI of 18.5 or below;(c)have a DSM-IV diagnosis of AN or Eating Disorder
Not Otherwise Specified (EDNOS). Our definition of
EDNOS is based on that by Thomas et al. [32] and
includes people who fulfill all criteria of AN, except
the weight criterion; those who fulfill all criteria for
AN but still have menses; those without a fat
phobia; and those with partial AN (defined as having
features of AN but missing at least two of the four
diagnostic criteria).
The decision to include EDNOS patients with a BMI
cut-off of 18.5 kg/m2 is supported by a recent large
meta-analysis of EDNOS which suggests that AN with a
more lenient weight criterion and without amenorrhea is
very similar to AN as defined currently [32]. We chose a
BMI cut-off of 18.5 as this is the WHO cut-off for being
underweight. Additionally, this BMI criterion was also
used in our previous study and in another large recent
AN trial [19,33].
Exclusion criteria
(a) life-threatening AN requiring immediate inpatient
treatment as defined in the UK NICE guidelines for
eating disorders [17];
(b)insufficient knowledge of English to understand the
treatment; learning disability; severe mental or
physical illness which needs treatment in its own
right (for example, psychosis or diabetes mellitus);
substance dependence or pregnancy.
We will not exclude patients on antidepressants, pro-
vided they are on a stable dose, that is, for at least four
weeks.
Outcome measures
All outcome measures will be collected at baseline, six
and twelve months, except the treatment credibility/ac-
ceptability visual analogue scale (VAS) which will be col-
lected only at six and twelve months. Potential
mediators of treatment outcome will also be collected at
three months (midtreatment).
Primary outcome
 Body Mass Index (kg/m2) at twelve months.
Secondary outcomes
 Body Mass Index (kg/m2) at six months.
 Eating Disorders Examination (EDE) global and
subscale scores [34]. The EDE is a widely used,
semi-structured interview that generates four
subscale scores: dietary restraint, eating concern,
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these four subscales is used to create a global
score. For patients unwilling/unable to do the EDE
interview, the questionnaire form of this
assessment (EDE-Q) will be used instead. The
EDE-Q has been found to have similar validity to
the EDE interview [35].
Other psychopathology The Depression, Anxiety and
Stress Scale - 21 (DASS-21) [36], Obsessive Compulsive
Inventory (OCI) [37].
Potential mediators The Cognitive Flexibility Scale
[38], Beliefs about Emotions Scale [39], The Emotion
Regulation Questionnaire [40] and a visual analog scale
(VAS) assessing motivation and social support.
Treatment credibility/acceptability
 Visual analog scales (VAS) of credibility and
acceptability of treatment, and use of what they have
learnt in treatment.
Neurocognitive and social-cognitive measures
(also potential moderators)
 The Wisconsin Card Sorting Task [41,42] assesses
cognitive flexibility (or set-shifting ability). It is a
commonly used task and involves matching stimulus
cards with one of four category cards. The stimuli
are multidimensional according to color, shape and
number.
 The Brixton Spatial Anticipation Task [43]. This also
measures set-shifting ability. Participants predict the
movement of a blue circle across 10 different
positions, adapting their predictions as the pattern
of movement changes.
 The Rey-Osterrieth Complex Figure Test [44,45].
This is a test of central coherence and evaluates
ability to plan, organize and assemble complex
information. Participants are asked to copy a
complex figure design.
 Baron-Cohen’s ‘Reading the Mind in Film’ task [46].
This measures complex Theory of Mind and
consists of viewing 22 brief film clips, after which
participants are asked to choose which of four
words best describes how the given character was
feeling at the end of the scene.
Costs and psychosocial impairment
 The Client Services Receipt Interview (CSRI) [47].
This is a self-report inventory of service use which
facilitates estimation of support costs. It will beadapted for the current study to cover a wide variety
of hospital, mental health, and community-based
services as well as medications, impact of
employment and additional personal expenditure
due to the eating disorder.
 The Clinical Impairment Assessment (CIA) [48].
This is a self-report measure of global psychosocial
impairment resulting from the individual’s eating
disorder behaviors.
Randomization
The generation and implementation of the randomiza-
tion sequence is conducted independently from the trial
team by the King’s Clinical Trials Unit (CTU). Once the
initial assessment has been carried out and the patient
recruited to the trial, the researcher enters patient ID
and stratifier details into the web-based CTU system.
Patients are then allocated to one of the two trial arms
using a restricted stratified randomization algorithm.
The strata will be (1) severity of weight loss (BMI below
or above 15), (2) AN-subtype (restricting or binge/purge)
and (3) previous admission within an eating disorder
inpatient unit, as these factors are known to affect
treatment outcome and rates of possible future
hospitalization. The stratification will be implemented
by minimized randomization with a random component.
The first N cases (N will not be disclosed) will be allo-
cated entirely at random to further enhance allocation
concealment.
Blinding and methods for protecting against other
sources of bias
It is not possible for patients or therapists to be blind to
the type of treatment. The research assessor, however,
will be blind to treatment allocation. In order to test
whether the researcher has remained blind to the treat-
ment allocation, they will be required to make a judg-
ment at the end of the twelve months assessment as to
which treatment they believe the person has received.
Sample size
We observed a mean weight gain of 7.3 kg (standard de-
viation 4 kg) in an unpublished series of nine pilot pa-
tients treated with MANTRA. The mean weight gain for
SSCM was previously estimated as 4 kg (McIntosh et al.
[18]). We derived a conservative estimate of the group
difference by a low estimate of the weight gain under
MANTRA (mean – 0.8 × standard error = 6.5 kg) minus
the weight gain estimate for SSCM; giving a difference
of 2.5 kg. A sample size of n = 55 per group will have
90% power to detect a difference in mean weight gain of
2.5 kg assuming a common weight gain standard devi-
ation of 4 kg (as per unpublished series of the nine pilot
patients) and using an independent samples t-test with a
Schmidt et al. Trials 2013, 14:160 Page 7 of 10
http://www.trialsjournal.com/content/14/1/160significance level of alpha = 0.05. Correcting for 20% at-
trition (as found in our previous studies), a total of 138
patients will be needed. (The sample size calculation was
not inflated for therapist effects because therapists were
crossed with treatments, which allows us to take account
of general therapist effects in the analysis, and
treatment-specific therapist effects were thought to be
negligible).
Recruitment
Patients will be recruited from several centers: South
London and Maudsley NHS Foundation Trust (catch-
ment area: two million); North East London Foundation
Trust Eating Disorders Service (catchment area
650,000); Barnet, Enfield & Haringey Mental Health
NHS Trust (catchment area five million); Oxford Health
NHS Foundation Trust (catchment area 1.1 million for
Oxfordshire and Buckinghamshire).
Data management
Data will be checked for entry errors by performing
double data entry for 10% of the data. Quality of the data
will be tested by examining the data for impossible
values by looking at data ranges. No post treatment data
will be released until the database is locked. Statistical
analysis will be blind to treatment arm.
Statistical analysis
Outcomes will be analyzed on an intention-to-treat
(ITT) basis, that is, participants will be analyzed in the
group to which they were randomized irrespective of
their compliance with the assigned scheme.
Primary outcome analysis
BMI at pretreatment (baseline), posttreatment (six
months) and follow-up (twelve months) will be analyzed
using a linear mixed effects model. In this model, the ex-
planatory variables with fixed effects are treatment
(MANTRA or SSCM), time (six months or twelve
months), the treatment x time interaction, baseline BMI
and randomization stratifiers (severity of weight loss,
AN-subtype, and previous hospitalization). Correlation
due to seeing the same therapist will be modeled by ran-
dom effects that vary at the level of the therapist (ac-
counting for general therapist effects) and a second set
of random effects that vary at the level of the therapist
within a specific treatment (a therapist x treatment
interaction accounting for therapy-specific therapist ef-
fects). Correlation due to repeated measures will be
accounted for by subject-varying random effects. Models
will be fitted using maximum likelihood [49]. Model fit-
ting will produce treatment effects estimates at
posttreatment (secondary BMI outcome) and twelve
months (primary BMI outcome). In the case of missingvalues in posttreatment BMI, the analysis is valid under
the missing at random (MAR) assumption which stipu-
lates that missingness is only driven by variables in-
cluded in the mixed model. We will summarize the
relation between demographic and clinical variables at
baseline and study drop-out by twelve months (that is,
those lost to follow-up or who actively withdrew from
the study). Any baseline variables found to be predictive
of missingness will be included as further explanatory
variables in the mixed model.
Adherence with allocated treatment will be measured
by the number of sessions attended and patients classi-
fied as ‘MANTRA completers’, ‘SSCM completers’ or
‘non-completers. Treatment completion will be defined
as attending a minimum of 15 out of 20 weekly sessions
[50]. In the case of non-adherence with randomized
treatments, the ITT estimate no longer provides an effi-
cacy assessment (only effectiveness under the current
setting) and we will estimate the outcome difference be-
tween those receiving SSCM and MANTRA (relative ef-
ficacy, or more specifically the complier average causal
effects or CACE) using instrumental variables methods
(see for example, Dunn et al. [51]).
Secondary outcome analyses
Secondary outcome variables are all continuous and will
be analyzed in the same way as the BMI variables. There
are a considerable number of assessments of treatment
effects on secondary outcomes. Thus interpretation of
these treatment effect estimates will need to take into
account the impact of multiple inferences.
Exploratory mediation assessment Four of the secon-
dary outcomes were chosen since they measure the core
maintenance factors targeted by the MANTRA interven-
tion. In other words these variables are putative media-
tors of the effect of MANTRA on patient ED outcomes.
We will use the Baron and Kenny regression approach
[52] to assess the potential of each of these four vari-
ables as mediators of patient ED outcomes (BMI and
EDE global score). Such analyses make restrictive as-
sumptions; the most important being that there is no
hidden confounding of the effect of the mediator on the
outcome. Thus we only use this as an exploratory ap-
proach to empirically re-formulate our basic (theoretical)
MANTRA process model. The parameters of this model
will yet have to be estimated without bias from future
studies that have been designed for mediation analysis.
Exploratory moderation assessment The study was
not powered to detect treatment effect modification by
baseline variables. We will carry out exploratory mode-
rator analyses by including interactions between treat-
ment and putative moderators (see potential moderators’
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will suggest moderation hypotheses to be investigated in
future trials.
All analyses will be carried out in Stata 12 [53].
Economic analysis
Service use patterns will be described and service costs
calculated using a well-established compendium of unit
costs [54] or those specifically estimated for this study,
using a comparable estimation method. Use of MAN-
TRA and SSCM will be recorded by therapists on the
case record form noting the number of sessions each
participant attended, the duration of each session and
details of staff involved in providing the intervention.
From these data, the cost of the intervention will be
estimated.
Cost-effectiveness analysis will then be conducted for
the period from baseline to twelve months follow-up
using the primary outcome measures, and the CIA.
Reporting of trial
The trial data will be reported in line with the exten-
sion of CONSORT guidance for trials assessing non-
pharmacological treatments [55,56].
Discussion
The aim of the MOSAIC study is to compare the effi-
cacy, cost and cost-effectiveness of two manual-based
treatments, MANTRA and SSCM, in adult outpatients
with AN and EDNOS-AN. The secondary aim is to ex-
plore mediators and potential moderators of treatment
outcome.
Psychotherapeutic interventions are the treatment of
choice for AN and related conditions. However, the
evidence-base for such treatments of adults with AN is
extremely limited. A number of small trials have tested a
range of therapies, yet there is no clear front runner.
There is an urgent need to develop more efficacious
treatments for adults with AN. Previous psychosocial
treatments for AN have been adapted from those for
other disorders and the effectiveness of a tailor-made
intervention is yet to be tested. MANTRA is a treatment
based on a specific maintenance model of AN. It draws
on neuropsychological, social-cognitive and personality
trait research in AN and includes both intra- and inter-
personal maintaining factors. It also has some prelimin-
ary evidence for acceptability and effectiveness among
the AN patient group [19,20].
The comparison treatment, SSCM, has been selected
as it was found to be superior to two other active treat-
ments [18] and is therefore a suitable alternative to
MANTRA. However, the advantages of SSCM appear to
fade over time [50]. Therefore longer-term follow-up is
needed to determine whether treatment effects of SSCMand MANTRA persist over time, which we plan to ex-
plore in future studies.
Potential implications
The MOSAIC study is the first large-scale RCT to com-
pare the efficacy of MANTRA and SSCM for adult out-
patients with AN or EDNOS-AN. The economic
analysis will give insight into the total cost of treating
the disorder and inform future best practice guidance.
The results of this study will provide a rigorous evalu-
ation of a novel treatment for AN (MANTRA) which
could be implemented in the NHS and made available to
services across the UK.
Strengths
This trial has a number of strengths. In particular the
large sample size provides sufficient power to draw
meaningful conclusions. Generalizability of results is fa-
cilitated by maximizing recruitment; four separate sites
participate in the study and the broad inclusion criteria
ensure inclusion of patients along the full spectrum of
AN severity. Therapist bias is reduced as all therapists
treat patients using both MANTRA and SSCM, and re-
search bias is reduced by researcher blinding to treat-
ment and stratified randomization. To help prevent trial
drop-out, treatment and research are kept separate.
Challenges
Maintaining motivation over the prolonged study period
may be challenging. All clinical and research personnel
involved in MOSAIC will receive a monthly newsletter
providing updates on recruitment, answering queries,
and offering encouragement to each NHS site. There
will also be a facility to allow anonymous feedback from
clinicians about their experience of the two interventions
and of taking part in an RCT. Quality control measures
have also been considered. To avoid therapeutic drift,
clinicians will receive ‘booster’ training days over the
course of the study and work using separate treatment
manuals. Therapists will attend weekly supervision by
senior clinicians. Supervision for MANTRA and SSCM
will be carried out separately to avoid contamination
across therapies. Psychotherapeutic sessions will be
audio taped and case record forms will be kept for indi-
vidual patients to ensure adherence to treatment proto-
col and the uniformity of treatment delivery. To aid in
participant retention we will keep a certain level of con-
tinuity in the researcher-participant pairing and collect
alternative contact information should participant cir-
cumstances change. Through understanding that re-
search assessments may seem arduous at times, we aim
to accommodate participants wherever possible by offer-
ing home visits, telephone interviewing and financial
reimbursement.
Schmidt et al. Trials 2013, 14:160 Page 9 of 10
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To conclude, this paper sets out a protocol for a multi-
center RCT that will enhance the current knowledge of
the relative efficacy of potential treatments for AN, using
a number of neuropsychological, social cognitive and
psychological measures.
Trial status
Recruitment for the trial is on-going. Data collection will
continue until end of 2013.
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